Higher Motor Activity in Schizophrenia Patients Treated With Olanzapine Versus Risperidone

被引:18
|
作者
Walther, Sebastian [1 ]
Horn, Helge [1 ]
Razavi, Nadja [1 ]
Koschorke, Philipp [1 ]
Wopfner, Alexander [1 ]
Mueller, Thomas J. [1 ]
Strik, Werner [1 ]
机构
[1] Univ Bern, Univ Hosp Psychiat, CH-3000 Bern 60, Switzerland
关键词
actigraphy; treatment effects; quantitative motor activity; ATYPICAL ANTIPSYCHOTICS; HALOPERIDOL; PSYCHOMOTOR; SYMPTOMS; SCALE; QUETIAPINE; MOVEMENTS; EFFICACY; SIGNS;
D O I
10.1097/JCP.0b013e3181d2ef6f
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There are indications that atypical antipsychotics differ in the probability of causing motor retardation. Whereas olanzapine seems to exert sedation, risperidone might slow patients because of parkinsonism or increased negative symptoms. Objective data on gross motor activity are not available. We present actigraphic data of 16 schizophrenia patients treated with olanzapine (mean dose, 21.1 mg/d) and 23 with risperidone (mean dose, 4.7 mg/d) to investigate possible differences in their effects on motor activity. Participants wore actigraphs continuously for 24 hours at the nondominant arm. Groups did not differ in age, Positive and Negative Syndrome Scale scores, duration of illness, and number of episodes. Patients treated with olanzapine had higher activity levels than those treated with risperidone (P = 0.024); this effect was robust and also present after covarying for chlorpromazine equivalents and Positive and Negative Syndrome Scale scores. Movement index (proportion of active episodes) and the average duration of immobility, however, failed to show any difference between groups. The results indicate that patients on olanzapine are more active during the day than patients on risperidone. It remains unclear whether this difference is due to subthreshold parkinsonism with risperidone or stronger beneficial effects of olanzapine on psychomotor slowing. Because the average duration of immobility remained unaffected, sedation is not likely to be the cause for the observed differences.
引用
收藏
页码:181 / 184
页数:4
相关论文
共 50 条
  • [1] Risperidone versus olanzapine for schizophrenia
    Jayaram, MB
    Hosalli, P
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (02):
  • [2] Risperidone versus olanzapine for schizophrenia
    Jayaram, M. B.
    Hosalli, P.
    Stroup, S.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (02):
  • [3] Risperidone versus olanzapine for treatment of schizophrenia
    Jayaram, Mahesh B.
    Hosalli, Prakash M.
    Stroup, Thomas S.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (06) : 1274 - 1276
  • [4] Glucose Metabolism in Japanese Schizophrenia Patients Treated With Risperidone or Olanzapine
    Yasui-Furukori, Norio
    Sato, Yasushi
    Furukori, Hanako
    Saito, Manabu
    Nakagami, Taku
    Kaneko, Sunao
    JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (01) : 95 - 100
  • [5] Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder
    Brecher, M
    SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 271 - 271
  • [6] Risperidone versus olanzapine in schizophrenia or schizoaffective disorder
    Conley, R
    Brecher, M
    BIOLOGICAL PSYCHIATRY, 1999, 45 (08) : 37S - 37S
  • [7] Olanzapine versus risperidone and haloperidol in treatment of schizophrenia
    Jones, B
    Tollefson, G
    SCHIZOPHRENIA RESEARCH, 1998, 29 (1-2) : 150 - 151
  • [8] Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone
    Kim, KS
    Pae, CU
    Chae, JH
    Bahk, WM
    Jun, TY
    Kim, DJ
    Dickson, RA
    JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (05) : 408 - 413
  • [9] Decreased bone mineral density in patients with schizophrenia treated with risperidone or olanzapine
    Wyszogrodzka-Kucharska, A.
    Rabe-Jablonska, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S408 - S409
  • [10] Prolactin response in patients with schizophrenia treated with haloperidol, clozapine, risperidone and olanzapine
    Potkonjak, Jelena
    Karlovic, Dalibor
    Bukovec, Zeljka
    Baricevic, Tihana
    BIOCHEMIA MEDICA, 2009, 19 (01) : 73 - 80